Avalanche & Regeneron join forces to develop next generation gene therapy products for the eye

Two US companies, Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) and Avalanche Biotechnologies, Inc announced the formation of a new collaboration to “discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases”. The collaboration is understood to cover novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche’s adeno-associated virus “(AAV)-based, proprietary, platform for the discovery and development of gene therapy vectors for ophthalmology”